ArticleCancers2025

Outcomes Following Radiotherapy for Oligoprogressive NSCLC on Immune Checkpoint Inhibitors: A Real-World, Multinational Experience.

Umair Mahmood et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.